Bioprinted pancreatic tissues successfully regulate blood glucose in animal models of type 1 diabetes
Vancouver, BC, Canada, October 13, 2021 - Aspect Biosystems, a biotechnology company pioneering the development of bioprinted cell therapies as medicines of the future, will present the Company’s latest data on its bioprinted pancreas therapeutic program at the International Pancreas and Islet Transplant Association Congress 2021, held virtually from October 20-23, 2021. This data highlights successful regulation of blood glucose in animal models of type 1 diabetes for 90 days post-implantation.
“We have significantly advanced our development of a cell-based bioprinted pancreas therapeutic by using in vitro and in vivo studies to demonstrate long-term tissue function and efficacy in restoring blood glucose to completely normal levels in animal models of type 1 diabetes,” said Dr. Sam Wadsworth, Chief Scientific Officer, Aspect Biosystems. “We look forward to sharing our new results at this leading conference, advancing our bioprinted therapeutic program towards clinical evaluation and, ultimately, introducing a transformative cure for diabetic patients dependent on insulin injections.”
- Presentation Title: Bioprinted immune-protective islet-containing tissues successfully regulate blood glucose in rodent models of type 1 diabetes
- Presenter: Dr. Valerio Russo, Lead Research Scientist at Aspect Biosystems
- Session Title: Bio-Engineering
- Date: Friday, October 22, 2021 at 12:00-1:20pm ET
Learn more about Aspect’s bioprinted therapeutic programs at www.aspectbiosystems.com/programs
About the International Pancreas and Islet Transplant Association (IPITA)
IPITA serves the pancreas and islet transplant scientific community in providing a forum for the open exchange of knowledge and expertise in order to facilitate the advancement of the clinical practice of pancreas and islet transplantation for the treatment of human diabetes. Learn more at www.ipita.org.
About Aspect Biosystems
Aspect Biosystems is a biotechnology company creating bioprinted therapeutics as medicines of the future. Aspect is applying its microfluidic 3D bioprinting technology internally to develop these advanced cell therapies and partnering with leading researchers and industry innovators worldwide to tackle the biggest challenges in regenerative medicine. Learn more at www.aspectbiosystems.com.